SCHEMBL227697

SCHEMBL227697

C#Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.67
LMNA P02545 1/20 0.62
CYP1A2 P05177 1/20 0.62
PTGS1 P23219 1/20 0.62
SLC6A2 P23975 1/20 0.62
CYP2C19 P33261 1/20 0.62
PTGS2 P35354 1/20 0.62
SLC6A3 Q01959 1/20 0.62
HIF1A Q16665 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
MAOA P21397 2/20 0.60
GAA P10253 1/20 0.60
MAPT P10636 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
BCHE P06276 1/20 0.56
NR4A1 P22736 1/20 0.55
NR4A2 P43354 1/20 0.55
NR4A3 Q92570 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18297574 0.92 APP (0.60) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL6749775 0.86 ALOX5 (0.67) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL339813 0.85 LMNA (0.82) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL27367676 0.85 LMNA (0.82) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL28385012 0.85 MEN1 (0.54) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL4768681 0.84 MAOB (0.49) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL14786201 0.83 MAOB (0.71) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL14786200 0.83 MAOB (0.71) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL28396179 0.82 LMNA (0.60) MAOBLMNACYP1A2PTGS1SLC6A2
SCHEMBL8773557 0.82 LMNA (0.60) MAOBLMNACYP1A2PTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115322644-B Modified alkynyl polymer coating constructed in situ at interface and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2023-06-02 CN claimed
CN-115322644-A Modified alkynyl polymer coating constructed in situ at interface and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2022-11-11 CN claimed
EP-0690855-B1 BENZOPYRANES AS POTASSIUM CHANNEL OPENERS PFIZER LTD (GB) 1996-12-18 EP claimed
CN-115322644-B Modified alkynyl polymer coating constructed in situ at interface and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2023-06-02 CN disclosed
CN-115322644-A Modified alkynyl polymer coating constructed in situ at interface and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2022-11-11 CN disclosed
CN-108368107-B Fused heterocyclic compounds as S1P modulators 艾伯维公司 2021-11-26 CN disclosed
CN-111807938-A (E) -1-chloro-2-iodoethylene compound and preparation method thereof 盐城工学院 2020-10-23 CN disclosed
CN-107406424-B Estrogen receptor modulators and uses thereof 豪夫迈·罗氏有限公司 2020-08-25 CN disclosed
CN-106536679-B Liquid-crystalline medium with homeotropic alignment 默克专利股份有限公司 2020-08-07 CN disclosed
EP-3233828-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2020-03-04 EP disclosed
US-10556907-B2 Fused heterocyclic compounds as S1P modulators AbbVie Deutschland GmbH & Co. KG (DE) 2020-02-11 US disclosed
EP-1470102-A1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) Applied Research Systems ARS Holding N.V. (AN) 2004-10-27 EP disclosed
WO-2004069843-A1 NOVEL TRICYCLIC AZEPINE DERIVATIVES, METHOD FOR PRODUCTION THEROF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME LES LABORATOIRES SERVIER (FR) 2004-08-19 WO disclosed
WO-2003064376-A1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-08-07 WO disclosed
EP-0540673-B1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1996-10-16 EP disclosed
US-5559144-A LIPOXYGENASE INHIBITORS, INHIBITORS OF BIOSYNTHESIS OF LEUKOTRIENES ABBOTT LABORATORIES (US) 1996-09-24 US disclosed
US-5476873-A Inhibit biosynthesis of leukotrienes ABBOTT LABORATORIES (US) 1995-12-19 US disclosed
EP-0540673-A4 1994-04-27 EP disclosed
EP-0540673-A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. ABBOTT LAB (US) 1993-05-12 EP disclosed
WO-1992001682-A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LABORATORIES (US) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556907-B2 Fused heterocyclic compounds as S1P modulators S1PR1, S1PR2, S1PR3 MAOB 3377/4885LMNA 2307/4885CYP1A2 3529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.